Endovascular Development AB is a Swedish AB, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2009, the company has 0 employees and reported revenue of SEK 0 in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolagets verksamhet ska vara att bedriva utveckling, tillverkning och kommersialisering av metoder och produkter relaterade till behandling av kärlsjukdomar, ägande och förvaltande av värdepapper, fastigheter båtar och fordon samt därmed förenlig verksamhet.
(no translation available)
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
In its most recent annual report (2022), Endovascular Development AB reported revenue of SEK 0, a decrease of 100% on the year before. The figures on this page draw on 5 annual filings covering 2018 to 2022. The bottom line showed a net loss of SEK 777.2k.
At the end of 2022, equity financed 12.9% of the balance sheet, and current assets covered short-term debt 664.9 times.
Frequently asked questions
What is the Org number of Endovascular Development AB?
Endovascular Development AB is registered with Bolagsverket / SCB under Org 5567830673.
Who is the chairman of Endovascular Development AB?
Carl Björn Krister Liungman chairs the board of Endovascular Development AB, in role since 2020.
